ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$1.99 USD
-0.08 (-3.86%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $2.00 +0.01 (0.50%) 7:22 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALXO 1.99 -0.08(-3.86%)
Will ALXO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
uniQure (QURE) Soars on New Huntington's Disease Study Data
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
Other News for ALXO
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi